People with high levels of omega-3 DHA in their blood have a 49% lower risk of developing Alzheimer’s

Advertisement

Neuroscience News logo for mobile.

Summary: People with higher levels of omega-3 DHA in their blood are 49% less likely to develop dementia than those with lower levels. Researchers say adding extra omega-3 DHA to the diet, particularly in people with the Alzheimer’s-associated Apoe4 gene, could slow the development and progression of dementia.

Source: Wright on Marketing and Communications

New research published today in nutrient shows that people with higher levels of DHA in their blood are 49% less likely to develop Alzheimer’s than those with lower levels, according to the Fatty Acid Research Institute (FARI).

The study, led by Aleix Sala-Vila, PhD, suggested that supplementation with dietary omega-3 DHA, particularly for those carrying the ApoE4 gene (which approximates a person’s susceptibility to developing AD doubled) could slow down the development of the disease.

A low-cost, low-risk nutritional intervention like this could potentially save billions in healthcare costs.

In this prospective observational study conducted within the Framingham Offspring Cohort – including 1490 dementia-free participants aged ≥ 65 years – researchers examined the association of docosahexaenoic acid (DHA) from red blood cells (RBC) and Alzheimer’s disease (AD) . Testing for interaction with the APOE-ε4 carrier ship.

The risk of AD events in the highest RBC-DHA quintile (Q5, >6.1%) was 49% lower than in the lowest quintile (Q1, <3.8%). It was predicted that an increase in RBC-DHA from Q1 to Q5 would provide an estimated 4.7 additional years of AD-free life.

In addition, the researchers noted that increased intake of DHA could reduce the risk of developing AD, particularly in higher-risk individuals, such as those who have diabetes.

The public health implications of preventing AD with something as simple as a dietary intervention like DHA are also significant.

The researchers noted, “Given the estimated 2021 healthcare spending for all patients with AD or other dementia in the United States of $355 billion (excluding care provided by family members and other unpaid caregivers), any cost-effective strategy to delay the onset of AD is a viable option is of greatest public health interest” and that “a 5-year delay in AD results in 2.7 additional years of life and 4.8 additional years of AD-free years for a person who would have acquired AD and is worth over $500,000 is.”

It was predicted that an increase in RBC-DHA from Q1 to Q5 would provide an estimated 4.7 additional years of AD-free life. The image is in the public domain

How does this paper compare to others in this area? “Our study is consistent with that of Tan et al. who reported cross-sectional associations with RBC-DHA in cognitive performance and measures of brain volume (with higher DHA being associated with beneficial outcomes) in the same cohort examined here,” said William S. Harris, PhD, President of FARI and senior author to this current study.

See also

This shows DNA

“Interestingly, 15 years ago similar results were obtained by Schaefer et al. in the parents of the subjects who were the focus of this study (ie, the original Framingham Heart Study cohort).

“Schafer et al. reported that participants in the upper quartile of plasma phosphatidylcholine DHA experienced a significant 47% reduction in risk of developing all-cause dementia compared to participants with lower levels,” continued Dr. Harris gone.

“Similar findings a generation apart in a similar genetic pool provide significant confirmation of this DHA-dementia relationship.”

About this news from Alzheimer’s research

Author: Becky Wright
Source: Wright on Marketing and Communications
Contact: Becky Wright – Wright on Marketing and Communications
Picture: The image is in the public domain

Original research: The results appear in nutrient

You May Also Like